EICHORPublic-registry site landscape for NCT02808104, “Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD)”, a Attention Deficit Disorder With Hyperactivity study sponsored by NLS Pharmaceutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT02808104 (registry record) |
| Study title | Mazindol Controlled Release in Adults With Attention Deficit Hyperactivity Disorder (ADHD) |
| Official title | A Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults With DSM-5 Attention Deficit Hyperactivity Disorder (ADHD) |
| Sponsor | NLS Pharmaceutics |
| Condition(s) | Attention Deficit Disorder With Hyperactivity |
| Phase | PHASE2 |
| Listed sites | 7 |
| Intervention(s) | mazindol |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT02808104.
Eichor generates a preliminary site-risk snapshot for NCT02808104 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
